Just an article I found. May interest those TTC or with unexplained infertility and done...

Hope this is useful or helpful or maybe just interesting.


Use of Crinone Demonstrates Excellent Pregnancy Rates

(Conjoint Annual Meeting of the American Society for Reproductive Medicine and the Canadian Fertility and Andrology Society) Interim findings from a study on progesterone supplementation in women undergoing assisted reproductive technologies (ART) indicate that the use of the progesterone gel Crinone as part of ART helped achieve pregnancy in over one third of the women and is a more convenient form of therapy than painful intramuscular injections. Crinone is administered vaginally once or twice daily using a pre-filled, disposable applicator. The study includes approximately 2,000 patients in 23 infertility treatment centers throughout the United States. These interim findings were based on 1,251 of those women from 16 centers who were undergoing in vitro fertilization in 1997 and 1998. Among patients whose data have been fully analyzed, 34.9 percent of 590 patients receiving Crinone in combination with follicle stimulating hormone achieved pregnancy, compared with 25.7 percent of the 210 patients receiving Crinone in combination with human menopausal gonadotropin. Part of the treatment protocol included having patients describe their experiences with progesterone therapies. Of patients who had previously undergone a different form of progesterone treatment, 91 percent preferred Crinone to intramuscular injections and 90 percent preferred Crinone to suppositories. In describing their overall experience with Crinone, about 94 percent of over 1,000 patients found Crinone to be easy to administer and reported no pain, and almost 75 percent did not think Crinone was messy. Crinone should not be given to patients with any of the following conditions: known sensitivity to Crinone (progesterone or any of the other ingredients); undiagnosed vaginal bleeding; liver dysfunction or disease; known or suspected malignancy of the breast or genital organs; missed abortion; active thrombophlebitis or thromboembolic disorders, or a history of hormone associated thrombophlebitis or thromboembolic disorders.

http://www.aafp.org/afp/20000415/conference.html

DAVID .L KEEFE, M.D.
Women and Infants Hospital
Providence, Rhode Island.